Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma

Vijaya R. Bhatt; Smith Giri; Vivek Verma; Sumit Dahal; Binay K. Shah; Ranjan Pathak; R. Gregory Bociek; Julie M. Vose; James O. Armitage

doi:10.2217/fon-2016-0048

Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma

Vijaya R. Bhatt, Smith Giri, Vivek Verma, Sumit Dahal, Binay K. Shah, Ranjan Pathak, R. Gregory Bociek, Julie M. Vose, James O. Armitage

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. Results: Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years. Conclusion: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.

Original language	English (US)
Pages (from-to)	1565-1575
Number of pages	11
Journal	Future Oncology
Volume	12
Issue number	13
DOIs	https://doi.org/10.2217/fon-2016-0048
State	Published - Jul 2016

Keywords

Hodgkin lymphoma
acute myeloid leukemia
survival

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2016-0048

Fingerprint Dive into the research topics of 'Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this

@article{e25b1b06f4c74096b322ed736f6434e6,

title = "Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma",

abstract = "Background: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. Results: Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years. Conclusion: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.",

keywords = "Hodgkin lymphoma, acute myeloid leukemia, survival",

author = "Bhatt, {Vijaya R.} and Smith Giri and Vivek Verma and Sumit Dahal and Shah, {Binay K.} and Ranjan Pathak and Bociek, {R. Gregory} and Vose, {Julie M.} and Armitage, {James O.}",

year = "2016",

month = jul,

doi = "10.2217/fon-2016-0048",

language = "English (US)",

volume = "12",

pages = "1565--1575",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "13",

}

TY - JOUR

T1 - Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma

AU - Bhatt, Vijaya R.

AU - Giri, Smith

AU - Verma, Vivek

AU - Dahal, Sumit

AU - Shah, Binay K.

AU - Pathak, Ranjan

AU - Bociek, R. Gregory

AU - Vose, Julie M.

AU - Armitage, James O.

PY - 2016/7

Y1 - 2016/7

N2 - Background: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. Results: Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years. Conclusion: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.

AB - Background: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. Results: Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years. Conclusion: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.

KW - Hodgkin lymphoma

KW - acute myeloid leukemia

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84975824221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975824221&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0048

DO - 10.2217/fon-2016-0048

M3 - Article

C2 - 27079926

AN - SCOPUS:84975824221

VL - 12

SP - 1565

EP - 1575

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 13

ER -